ABD - İngilizce - NLM (National Library of Medicine)

bausch health us, llc - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 ml - locoid® lotion is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. none. pregnancy   risk summary there are no controlled or large-scale epidemiologic studies with locoid lotion in pregnant women, and available data on hydrocortisone butyrate use in pregnant women have not identified a drug associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. in animal reproduction studies, when administered subcutaneously or topically to pregnant rats, rabbits, and mice, hydrocortisone butyrate induced adverse reproductive and developmental outcomes, including abortion, fetal death, malformation, delayed ossification, decrease in fetal weight, and delay in sexual maturation (see data) . the available data do not allow the calculation of relevant comparisons between the systemic exposure of hydrocortisone butyrate observed in animal studies and the systemic exposure that would be expected in humans after topical use of lo

ABD - İngilizce - NLM (National Library of Medicine)

bausch health us, llc - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 g - locoid lipocream is indicated for: none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. therefore, locoid lipocream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topical human dose (mthd) for hydrocortisone butyrate cream (25 g). systemic embryofetal development studies were conducted in rats and rabbits. subcutaneous doses of 0.6, 1.8, and 5.4 mg/kg/day hydrocortisone butyrate were administered to pregnant female rats during gestation days 6 - 17. in the

ABD - İngilizce - NLM (National Library of Medicine)

onset dermatologics, llc - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 g

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

apotex nz ltd - hydrocortisone butyrate 0.1%{relative} - topical cream - 0.1% w/w - active: hydrocortisone butyrate 0.1%{relative}

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - hydrocortisone butyrate 0.1%{relative} - scalp lotion - 0.1% w/v - active: hydrocortisone butyrate 0.1%{relative}

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - hydrocortisone butyrate 0.1%{relative} - topical cream - 0.1% w/w - active: hydrocortisone butyrate 0.1%{relative}

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - hydrocortisone butyrate 0.1%{relative} - topical ointment - 0.1% w/w - active: hydrocortisone butyrate 0.1%{relative}

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - hydrocortisone butyrate 0.1%{relative} - topical cream - 0.1% w/w - active: hydrocortisone butyrate 0.1%{relative}

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - hydrocortisone butyrate - ointment - 100microgram/1gram

ABD - İngilizce - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets, usp are indicated in the following conditions: 1.   endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3.   collagen diseases during an exacerbation or as maintenance therapy in selected cases of: